A detailed history of Westmount Partners, LLC transactions in Pfizer Inc stock. As of the latest transaction made, Westmount Partners, LLC holds 8,826 shares of PFE stock, worth $221,356. This represents 0.06% of its overall portfolio holdings.

Number of Shares
8,826
Previous 13,991 36.92%
Holding current value
$221,356
Previous $339 Million 29.19%
% of portfolio
0.06%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 14, 2025

SELL
$23.29 - $25.88 $120,292 - $133,670
-5,165 Reduced 36.92%
8,826 $240 Million
Q2 2025

Jul 09, 2025

SELL
$21.59 - $24.84 $19,582 - $22,529
-907 Reduced 6.09%
13,991 $339 Million
Q1 2025

May 01, 2025

BUY
$25.01 - $27.13 $175 - $189
7 Added 0.05%
14,898 $378 Million
Q4 2024

Jan 13, 2025

SELL
$24.8 - $30.19 $40,746 - $49,602
-1,643 Reduced 9.94%
14,891 $395 Million
Q3 2024

Jan 13, 2025

BUY
$27.7 - $31.39 $457,991 - $519,002
16,534 New
16,534 $478 Million
Q2 2024

Jan 28, 2025

SELL
$25.26 - $29.6 $33,166 - $38,864
-1,313 Reduced 7.07%
17,262 $487 Million
Q1 2024

Jan 28, 2025

BUY
$25.89 - $29.73 $42,925 - $49,292
1,658 Added 9.8%
18,575 $515 Million
Q4 2023

Jan 28, 2025

SELL
$26.13 - $33.94 $41,442 - $53,828
-1,586 Reduced 8.57%
16,917 $487 Million
Q3 2023

Jan 28, 2025

SELL
$32.09 - $37.51 $25,639 - $29,970
-799 Reduced 4.14%
18,503 $614 Million
Q2 2023

Jan 28, 2025

BUY
$36.12 - $41.79 $159,325 - $184,335
4,411 Added 29.62%
19,302 $708 Million
Q1 2023

Jan 29, 2025

BUY
$39.39 - $51.28 $171,937 - $223,837
4,365 Added 29.31%
19,256 $786 Million
Q4 2022

Jan 28, 2025

BUY
$41.75 - $54.5 $234,426 - $306,017
5,615 Added 37.71%
20,506 $1.05 Billion

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $141B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Westmount Partners, LLC Portfolio

Follow Westmount Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Westmount Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Westmount Partners, LLC with notifications on news.